The reduction ratios of SUVmax for the prostate tumor, metastatic lymph nodes, and metastatic bone lesions were 49%, 74%, and 63%, respectively, with those of PSMA-TV and PSMA-TL being 50%, 89%, and 65% and 70%, 92%, and 73%, respectively. The gene discussed is FOLH1; the disease is prostate neoplasm.